Go Pro
→ Elon gets it. Do you? (From Porter & Company) (Ad)tc pixel
NASDAQ:KZIA

Novogen Q2 2026 Earnings Report

Novogen logo
$9.60 -1.32 (-12.09%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$9.90 +0.30 (+3.13%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Novogen EPS Results

Actual EPS
-$1.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novogen Revenue Results

Actual Revenue
$4.89 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novogen Announcement Details

Quarter
Q2 2026
Date
2/14/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Novogen Earnings Headlines

Novogen Limited (NASDAQ:KZIA) Receives Average Recommendation of "Moderate Buy" from Brokerages
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31043140
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
September 22 at 7:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-sovargen-co-doses-first-patient-in-phase-1b2a-trial-of-paxalisib-for-rare-seizure-disorders-302883753.html
Elon gets it. Do you?
Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.tc pixel
September 24 at 1:00 AM  |  Porter & Company (Ad)
Novogen Limited (NASDAQ:KZIA) Sees Significant Increase in Short Interest
September 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033198
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
September 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-first-patient-dosed-in-pnoc035-clinical-study-evaluating-paxalisib-for-recurrent-pediatric-atrt-brain-cancer-302873103.html
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript
September 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943248-kazia-therapeutics-limited-kzia-discusses-clinical-and-corporate-updates-with-focus-on
See More Novogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novogen and other key companies, straight to your email.

About Novogen

Novogen (NASDAQ:KZIA), now known as Kazia Therapeutics Limited, is an Australia-based biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research has centered on targeted treatments designed to address tumors that are difficult to treat with conventional approaches.

Kazia’s principal clinical program has been paxalisib, an orally administered inhibitor of the PI3K/mTOR pathway being investigated primarily for brain cancers, including glioblastoma. The company has also pursued other oncology candidates, including therapies intended to inhibit tumor growth and angiogenesis.

Founded in Australia, Novogen developed its early drug-discovery and oncology programs before changing its name to Kazia Therapeutics in 2016. The company’s activities have included collaborations and clinical development programs involving research institutions and trial sites in Australia, the United States, and other international markets.

View Novogen Profile
Earnings Tools